Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR

Journal of Clinical Pathology

Volumn 61, Issue 1, 2008, Pages 109-114

  Schumacher, J A ^a   Elenitoba Johnson, K S J ^a,b   Lim, Megan S ^a,b,c  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; OLIGONUCLEOTIDE; PARAFFIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ALLELE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EXON; HUMAN; HUMAN TISSUE; MUTANT; MUTATION; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEMINOMA; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SITE DIRECTED MUTAGENESIS; SYSTEMIC MASTOCYTOSIS; WILD TYPE; BONE MARROW; EVALUATION; GENETICS; MALE; METHODOLOGY; MOLECULAR CLONING; PATHOLOGY; TESTIS TUMOR;

ALLELES; BASE SEQUENCE; BONE MARROW; CLONING, MOLECULAR; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 38449108455     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.047928     Document Type: Article

References (28)

1. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
2. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96:1609-14.
3. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005;114:41- 51.
4. Shiohara M, Koike K. Regulation of mast cell development. Chem Immunol Allergy 2005;87:1-21.
5. Price ER, Ding HF, Badalian T, et al. Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. J Biol Chem 1998;273:17983-6.
6. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
7. Blume-Jensen P, Ronnstrand L, Gout I, et al. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. J Biol Chem 1994;269:21793-802.
8. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999;31:1053-74.
9. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-15.
10. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13:205-20.
11. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
12. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004;164:305-13.
13. Willmore-Payne C, Holden JA, Hirschowitz S, et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 2006;37:520-7.
14. Kohl TM, Schnittger S, Ellwart JW, et al. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005;105:3319-21.
15. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140-7.
16. Buttner C, Henz BM, Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227-31.
17. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-39.
18. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
19. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
20. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006;26:575-92.
21. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.
22. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-91.
23. Corless CL, Harrell P, Lacouture M, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukaemia. J Mol Diagn 2006;8:604-12.
24. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737-46.
25. Tan A, Westerman D, McArthur GA, et al. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006;52:2250-7.
26. Rhodes CH, Honsinger C, Porter DM, et al. Analysis of the allele-specific PCR method for the detection of neoplastic disease. Diagn Mol Pathol 1997;6:49-57.
27. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:397-411, quiz 526.
28. Kanakura Y, Furitsu T, Tsujimura T, et al. Activating mutations of the c-kit protooncogene in a human mast cell leukemia cell line. Leukemia 1994;8:S18-22.